Atticus Capital, the activist hedge fund firm run by Timothy Barakett, has purchased options giving it additional exposure to pharmaceutical company AtheroGenics. The firm entered into one transaction earlier this month where it acquired the option to purchase 100,000 shares at USD11.59, according to a filing with the Securities and Exchange Commission. AtheroGenics was trading around USD12.25 as DW went to press last week.
This follows three transactions in November where Atticus purchased options referencing AtheroGenics. One gave the firm the option to purchase 145,100 shares at a strike price of USD13.6. A second gave it the right to snag 116,900 shares at USD13.49, while the third option was for 38,000 shares at USD13.38. Calls to Atticus were not returned by press time.
